Session Details

F043 Choose Your Own Adventure: Crowdsourcing for the Management of Complex and Refractory Pediatric Dermatology Cases

Sat, Mar 20, 3:30 PM - 5:30 PM
2 CME Available Forum ARS

DESCRIPTION

This session will present five pediatric dermatology cases for which there is limited, published, evidence-based consensus data on management. Using audience response software, we will ask audience attendees to select their preferred next steps in work-up and complex therapeutic management. Panelist pediatric dermatology experts will reflect on crowdsourced answers and provide additional clinical pearls based on their clinical experience.

LEARNING OBJECTIVES

1.

Recognize the limits of current evidence regarding the management of certain complex and refractory pediatric dermatologic conditions (i.e. acne fulminans; recalcitrant alopecia areata; recurrent DFSP)

2.

Formulate nuanced management approaches and therapeutic algorithms for the above challenging pediatric dermatologic cases

3.

Incorporate management pearls from expert pediatric dermatologists into the approach of complex and refractory pediatric cases

DIRECTOR

Robert J. Smith, MD, FAAD

Robert J. Smith, MD, FAAD

Johns Hopkins University School of Medicine

SPEAKERS

Nessa Aghazadeh Monandesi, MD, FAAD

Nessa Aghazadeh Monandesi, MD, FAAD

Mayo Clinic

Sarah Jane Coates, MD, FAAD

Sarah Jane Coates, MD, FAAD

Michelle Oboite, MD, FAAD

Michelle Oboite, MD, FAAD

DISCLOSURES

Nessa Aghazadeh Monandesi, MD, FAAD

Abeona Therapeutics – Advisory Board(Honoraria); AlphaSights – Consultant (1099 relationship)(Fees); Chiesi Farmaceutici – Advisory Board(Honoraria); Leo Pharma – Consultant (1099 relationship)(Honoraria); Mosaic Research Management – Consultant (1099 relationship)(Fees); The Dedham Group – Consultant (1099 relationship)(Fees);

Sarah Jane Coates, MD, FAAD

No financial relationships exist with ineligible companies.

Michelle Oboite, MD, FAAD

Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);

Robert J. Smith, MD, FAAD

No financial relationships exist with ineligible companies.